Bone turnover markers and their role in Osteoporosis after treatment with Atripla compared with Truvada and raltegravir in HIV patients
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary)
- Indications HIV infections
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
Most Recent Events
- 21 Dec 2018 New trial record
- 31 Oct 2018 Results presented at the 14th International Congress on Drug Therapy and HIV Infection